Sandra Coral

Sandra Coral

Auto-generated profile, based on publicly available information

Sandra Coral

Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, 53100 Siena, Italy

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2011 in Molecular Oncology
Verified
Journal Article
Closed access
EFElisabetta Fratta
Elisabetta Fratta
SCSandra Coral
Sandra Coral
ACAlessia Covre
Alessia Covre
GPGiulia Parisi
Giulia Parisi
FCFrancesca Colizzi
Francesca Colizzi
MMMichele Maio
Michele Maio

15 December 2004 in Cancer Research
Verified
Journal Article
Closed access
PDF file
LSLuca Sigalotti
Luca Sigalotti
EFElisabetta Fratta
Elisabetta Fratta
SCSandra Coral
Sandra Coral
STSilvia Tanzarella
Silvia Tanzarella
RDRiccardo Danielli
Riccardo Danielli
MMMichele Maio
Michele Maio
Cancer/testis antigens (CTA) are suitable targets for immunotherapy of human malignancies, and clinical trials are mainly focusing on MAGE-A3. However, the heterogeneous intratumor expression of CTA may hamper the effectiveness of CTA-directed vaccination through the emergence of CTA-negative neoplastic clones. We investigated the intratumor heterogeneity of CTA in human melanoma and the underlying molecular mechanism(s) at clonal level using 14 single cell clones generated from the melanoma lesion Mel 313. Reverse transcription-PCR revealed a highly heterogeneous expression of MAGE-A1, -A2, -A3, -A4, -A6, GAGE 1–6, SSX 1–5, and PRAME among melanoma clones. Only nine clones expressed MAGE-A3 and competitive reverse transcription-PCR identified relative differences in the number of mRNA molecules of up to 130-fold between clones 5 and 14. This clonal heterogeneity of MAGE-A3 expression correlated with the methylation status of specific CpG dinucleotides in MAGE-A3 promoter: i.e., hypomethylated CpG dinucleotides at positions −321, −151, −19, −16, −5, −2, +21, and +42 were found in clones expressing high but not low levels of MAGE-A3. Supporting the role of DNA methylation in generating the intratumor heterogeneity of CTA, the DNA hypomethylating agent 5-aza-2′-deoxycytidine (5-AZA-dCyd) invariably induced their expression in all CTA-negative clones. Furthermore, 5-AZA-dCyd–treatment reduced to 6 folds the differential expression of MAGE-A3 between clones 5 and 14, which became recognized to a similar extent by T cells specific for a MAGE-A–encoded peptide. These findings identify promoter methylation as directly responsible for the intratumoral heterogeneity of therapeutic CTA in melanoma and foresee the use of 5-AZA-dCyd to overcome the limitations set by their intratumor heterogeneous expression to CTA-based vaccine therapy.

25 May 2001 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
EFEster Fonsatti
Ester Fonsatti
LVLuigi Del Vecchio
Luigi Del Vecchio
MAMaresa Altomonte
Maresa Altomonte
LSLuca Sigalotti
Luca Sigalotti
MNMaria Rita Nicotra
Maria Rita Nicotra
MMMichele Maio
Michele Maio

29 May 2007 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
LSLuca Sigalotti
Luca Sigalotti
EFElisabetta Fratta
Elisabetta Fratta
SCSandra Coral
Sandra Coral
ECEnzo Cortini
Enzo Cortini
ACAlessia Covre
Alessia Covre
MMMichele Maio
Michele Maio

1 January 1999 in Journal of Immunotherapy
Verified
Journal Article
Closed access
SCSandra Coral
Sandra Coral
LSLuca Sigalotti
Luca Sigalotti
AGAldo Gasparollo
Aldo Gasparollo
ICIlaria Cattarossi
Ilaria Cattarossi
AVAlberto Visintin
Alberto Visintin
MMMichele Maio
Michele Maio
Summary: The immunogenic potential of melanoma cells and their recognition by the host's cytotoxic cells depends on the presence and on the level of expression of human leukocyte antigen (HLA) class I antigens, costimulatory molecules and melanoma- associated antigens (MAA), on neoplastic cells. In this study, we demonstrate that the DNA hypomethylating agent 5-aza-2'-deoxycytidine (5-AZA-CdR), significantly (p<0.05) enhanced the constitutive expression of HLA class I antigens, HLAAl and -A2 alleles, and of the costimulatory molecules intercellular adhesion molecule- 1 and lymphocyte function-associated antigen-3, on a panel of 12 melanoma cells. This upregulation peaked at day 4, slowly decreased thereafter, and returned to baseline levels 32 days after the end of treatment. In addition, treatment with 5-AZACdR induced a persistent expression of MAGE-1 in Mel 275 melanoma cells; this was still detectable, by reverse transcriptase polymerase chain reaction, 60 days after the end of treatment. In contrast, 5-AZA-CdR did not affect the constitutive expression of the high molecular weight-MAA by the melanoma cells investigated. These observations, together with data obtained comparing the effect of 5-AZA-CdR with that of interferon-7, strongly suggest that 5-AZA-CdR may have prospective therapeutic implications in active and/or passive specific immunotherapy for human melanoma.

1 June 2014 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
LSLuca Sigalotti
Luca Sigalotti
EFElisabetta Fratta
Elisabetta Fratta
SCSandra Coral
Sandra Coral
MMMichele Maio
Michele Maio